Key points are not available for this paper at this time.
Abstract Purpose Oligodendrogliomas (ODGs) are a subtype of diffuse lower-grade gliomas with overall survival of >10 years. This study aims to analyze long-term outcomes and identify prognostic factors in patients with WHO grade 2 isocitrate dehydrogenase (IDH)-mutant, 1p19q-codeleted ODG. Methods We retrospectively reviewed 138 adult patients diagnosed with WHO grade 2 IDH-mutant, 1p19q-codeleted ODG who underwent surgical resection or biopsy between 1994 and 2021, analyzing clinical data, treatment details, and outcomes. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan–Meier analysis. Univariate and multivariate Cox regression analyses were utilized to identify significant prognostic factors. Results In the gross total resection (GTR) group, 63 (45.7%) underwent observation and 5 (3.6%) received postoperative treatment; in the subtotal resection (STR) or biopsy group, 37 (26.8%) were observed and 33 (23.9%) received postoperative treatment. The median PFS and OS were 6.8 and 18.4 years, respectively. Between adjuvant treatment and observation, there was no significant difference in PFS or OS. However, GTR exhibited significantly better PFS and OS compared to STR or biopsy (p = 0.043 and 0.014, respectively). Multivariate analysis revealed that contrast enhancement on MRI was associated with worse PFS (HR = 2.08, p = 0.004) and OS (HR = 5.89, p = 0.001). And the presence of seizures at presentation was associated with improved OS (HR = 0.21, p = 0.002). Conclusion This study underscores favorable long-term outcomes for patients with IDH-mutant, 1p19q-codeleted ODG WHO grade 2. Our findings indicate that GTR plays a crucial role in enhancing PFS and OS in WHO grade 2 ODG.
Byeon et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: